Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Summary for Oncology Continued strong execution and portfolio rejuvenation in 2021, with growth drivers up 17% Driving share gains with KisqaliⓇ in CDK4/6 class, ahead of NATALEE adjuvant readout Focusing on launch execution for ScemblixⓇ and 177Lu-PSMA-617; preparing for next wave of launches 38 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation